Defence Provides Update on Delivery of AGSM Proxy Materials
Defence Therapeutics announces its annual general and special meeting of shareholders scheduled for December 12th, 2024, at 10:00 a.m. (Pacific Time) in Vancouver. Shareholders of record as of November 4, 2024, are eligible to vote, with a proxy deadline of December 10th, 2024, at 10:00 a.m. Due to a Canada Post labour strike, shareholders may experience delays in receiving the Information Circular dated November 8, 2024. The company encourages shareholders to access materials electronically via SEDAR+ and vote according to the Circular's instructions.
Defence Therapeutics annuncia la sua assemblea generale e speciale annuale degli azionisti, prevista per il 12 dicembre 2024, alle 10:00 (ora del Pacifico) a Vancouver. Gli azionisti registrati al 4 novembre 2024 sono idonei a votare, con una scadenza per la delega fissata al 10 dicembre 2024, alle 10:00. A causa di uno sciopero dei lavoratori di Canada Post, gli azionisti potrebbero subire ritardi nella ricezione del Circular Informativo datato 8 novembre 2024. La società invita gli azionisti a accedere ai materiali elettronicamente tramite SEDAR+ e a votare secondo le istruzioni del Circular.
Defence Therapeutics anuncia su reunión general y especial anual de accionistas programada para el 12 de diciembre de 2024, a las 10:00 a.m. (Hora del Pacífico) en Vancouver. Los accionistas registrados a partir del 4 de noviembre de 2024 son elegibles para votar, con una fecha límite para la delegación establecida para el 10 de diciembre de 2024, a las 10:00 a.m. Debido a una huelga laboral de Canada Post, los accionistas pueden experimentar retrasos en la recepción del Circular de Información con fecha del 8 de noviembre de 2024. La empresa anima a los accionistas a acceder a los materiales electrónicamente a través de SEDAR+ y a votar de acuerdo con las instrucciones del Circular.
Defense Therapeutics는 2024년 12월 12일 오전 10시(태평양 표준시)에 밴쿠버에서 열릴 주주 총회 및 특별 회의를 발표했습니다. 2024년 11월 4일 기준으로 등록된 주주는 투표 자격이 있으며, 위임장 제출 마감일은 2024년 12월 10일 오전 10시입니다. 캐나다 공사 파업으로 인해 주주들은 2024년 11월 8일자 정보 서신을 받는 데 지연을 겪을 수 있습니다. 회사는 주주들에게 SEDAR+를 통해 전자적으로 자료에 접근하고 서신의 지침에 따라 투표할 것을 권장합니다.
Defence Therapeutics annonce sa réunion générale annuelle et spéciale des actionnaires prévue pour le 12 décembre 2024 à 10h00 (heure du Pacifique) à Vancouver. Les actionnaires enregistrés au 4 novembre 2024 sont éligibles pour voter, avec une date limite de procuration fixée au 10 décembre 2024 à 10h00. En raison d'une grève des travailleurs de Canada Post, les actionnaires peuvent connaître des retards dans la réception du Circulaire d'Information datée du 8 novembre 2024. La société encourage les actionnaires à accéder aux documents électroniquement via SEDAR+ et à voter selon les instructions du Circulaire.
Defence Therapeutics kündigt seine jährliche Haupt- und Sonderversammlung der Aktionäre an, die für den 12. Dezember 2024 um 10:00 Uhr (Pazifische Zeit) in Vancouver geplant ist. Aktionäre, die am 4. November 2024 registriert sind, sind wahlberechtigt, wobei die Frist für eine Vollmacht am 10. Dezember 2024 um 10:00 Uhr endet. Aufgrund eines Arbeitsstreiks bei Canada Post können Aktionäre Verzögerungen beim Erhalt des Informationsrundschreibens vom 8. November 2024 erfahren. Das Unternehmen ermutigt die Aktionäre, die Unterlagen elektronisch über SEDAR+ abzurufen und gemäß den Anweisungen des Rundschreibens zu wählen.
- None.
- None.
Vancouver, British Columbia--(Newsfile Corp. - December 2, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is to hold its annual general and special meeting of the shareholders (the "Shareholders") of the Company on December 12th, 2024 at 10:00 a.m. (Pacific Time) at the office of McMillan LLP located at Royal Center, 1055 W. Georgia Street, Suite 1500, Vancouver, British Columbia (the "Meeting").
The Shareholders of record as of the close of business on November 4, 2024, are entitled to receive notice of and to vote at the Meeting. The Shareholders are urged to vote before the proxy deadline of 10:00 a.m. on December 10th, 2024.
The Information Circular of the Company dated November 8, 2024 (the "Circular") provides important information on the matters to be approved by the Shareholders at the Meeting and voting procedures. The Circular is being delivered to the Shareholders in compliance with applicable Canadian securities laws and available under the Company's profile on SEDAR+ at www.sedarplus.ca.
Due to the ongoing Canada Post labour strike, the Shareholders may experience a delay in receiving the Circular and related materials in respect of the Meeting. All Shareholders are encouraged to access the Circular and related materials electronically and to vote in accordance with the instructions set forth in the Circular. Registered shareholders should complete all signed proxy forms as directed on the form of proxy no later than 48 hours prior to the Meeting. Beneficial owners can obtain a copy of the voting instructions form from their intermediary.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232219
FAQ
When is Defence Therapeutics (DTCFF) holding its 2024 annual general meeting?
What is the voting deadline for Defence Therapeutics (DTCFF) 2024 annual meeting?
How can shareholders access Defence Therapeutics (DTCFF) meeting materials during the Canada Post strike?
What is the record date for Defence Therapeutics (DTCFF) 2024 annual meeting?
